TOP 10 Oncologia de Precisão
OSWALDO CRUZ
11/19/21, 11:00 AM
America/Sao_Paulo GMT -3
Description
08:00 - 08:20
ARTIGO 1 - KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
Hong, D. N Engl J Med 2020; 383:1207
- Palestrante FERNANDO SANTINI
08:20 - 08:40
ARTIGO 2 - Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena, S. Lancet Oncol 2021; 22(6):779
- Palestrante RODRIGO GUEDES
08:40 - 09:00
ARTIGO 3 - Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Oark, K. J Clin Oncol 2021; JCO2100662
- Palestrante SAMIRA MASCARENHAS
09:00 - 09:20
ARTIGO 4 - Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer.
Wu, Y. N Engl J Med 2020; 383:1711
- Palestrante GUSTAVO STOCK
09:20 - 09:40
ARTIGO 5 - Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle, M. Lancet Gastroenterol Hepatol 2021; 6(10):803
- Palestrante RICARDO CAPONERO
09:40 - 10:00
ARTIGO 6 - Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri, T. Nat Med 2021; 27(5):802
- Palestrante FABIO SCHUTZ
10:00 - 10:40
INTERVALO
10:40 - 11:00
ARTIGO 7 - Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Abida, W. J Clin Oncol 2020; 38(32):3763
- Palestrante ANDRE MURAD
11:00 - 11:20
ARTIGO 8 - Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Blay, JY. Lancet Oncol 2020; 21(7):923
- Palestrante RENATA D’ALPINO
11:20 - 11:40
ARTIGO 9 - Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor, O. N Engl J Med 2021 Jun 23. Online ahead of print
- Palestrante ARIEL KANN
11:40 - 12:00
ARTIGO 10 - Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh, A. Clin Cancer Res 2021 Apr 29. Online ahead of print
- Palestrante ALESSANDRO LEAL
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Marcos André Costa
ARTIGO 1 - KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors, ARTIGO 2 - Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, ARTIGO 3 - Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, ARTIGO 4 - Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer, ARTIGO 5 - Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, ARTIGO 6 - Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis, ARTIGO 7 - Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration, ARTIGO 8 - Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, ARTIGO 9 - Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, ARTIGO 10 - Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Inglês
Speakers
FERNANDO SANTINI, RODRIGO GUEDES, SAMIRA MASCARENHAS, GUSTAVO STOCK, RICARDO CAPONERO, FABIO SCHUTZ, ANDRE MURAD, RENATA D’ALPINO, ARIEL KANN, ALESSANDRO LEAL
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.